Notify me when STEMPOINT CAPITAL LP files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| SRZN | Surrozen, Inc. | Common Stock, $0.0001 par value per share | 11.4% | $8,952,696 | $3,926,731 | 1,016,197 | +78% | StemPoint Capital LP | 30 Jun 2025 |
| VTGN | Vistagen Therapeutics, Inc | Common Stock, par value $0.001 per share ("Shares") | 8.2% | $5,448,671 | 2,328,492 | StemPoint Capital LP | 31 Dec 2024 | ||
| XLO | Xilio Therapeutics, Inc. | Common Stock, par value $0.0001 per share | 7.2% | $3,371,600 | 4,000,000 | StemPoint Capital LP | 30 Sep 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|